Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
| Revenue (TTM) | $4.54B |
| Gross Profit (TTM) | $3.07B |
| EBITDA | $1.14B |
| Operating Margin | 20.00% |
| Return on Equity | 32.40% |
| Return on Assets | 8.32% |
| Revenue/Share (TTM) | $29.86 |
| Book Value | $20.69 |
| Price-to-Book | 10.00 |
| Price-to-Sales (TTM) | 7.10 |
| EV/Revenue | 7.14 |
| EV/EBITDA | 22.64 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | 4.20% |
| Shares Outstanding | $151.20M |
| Float | $150.70M |
| % Insiders | 0.21% |
| % Institutions | 110.65% |
Volatility is currently expanding
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Explore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.
The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference Jefferies Global Healthcare Conference on November 17, 2026 The fireside chat is scheduled for 02:30am PT (10:30am GMT). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ILMN and any ticker you trade — then tracks every position and per-strategy win rate.
